<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rifabutin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00615</strong>&#160; (APRD00094)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in <span class="caps">HIV</span>-positive patients. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00615/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00615/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00615.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00615.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00615.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00615.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00615.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00615">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ansamicin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Ansamycin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Rifabutin</td><td>German</td><td>INN</td></tr><tr><td>Rifabutina</td><td>Spanish/Italian</td><td>INN/DCIT</td></tr><tr><td>Rifabutine</td><td>French</td><td>INN</td></tr><tr><td>Rifabutinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Ansatipin</td><td>Pfizer</td></tr><tr><td>Ansatipine</td><td>SERB</td></tr><tr><td>Mycobutin</td><td>Pfizer</td></tr><tr><td>Ributin</td><td>Lupin</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/antibiotics-antitubercular">Antibiotics, Antitubercular</a></li></ul></td></tr><tr><th>CAS number</th><td>72559-06-9</td></tr><tr><th>Weight</th><td>Average: 847.0047<br>Monoisotopic: 846.441508846</td></tr><tr><th>Chemical Formula</th><td>C<sub>46</sub>H<sub>62</sub>N<sub>4</sub>O<sub>11</sub></td></tr><tr><th>InChI Key</th><td>ATEBXHFBFRCZMA-VXTBVIBXSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthofurans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Naphthofurans</td></tr><tr><th>Alternative parents</th><td>Azaspirodecane Derivatives; Naphthalenes; Benzofurans; Ortho Cresols; Toluenes; Alkyl Aryl Ethers; Piperidines; Imidazolines; Ketones; Tertiary Amines; Polyols; Secondary Carboxylic Acid Amides; Secondary Alcohols; Carboxylic Acid Esters; Carboxylic Acids; Enolates; Enols; Polyamines; Acetals</td></tr><tr><th>Substituents</th><td>acene; azaspirodecane; naphthalene; benzofuran; o-cresol; phenol derivative; alkyl aryl ether; toluene; piperidine; benzene; 3-imidazoline; ketone; polyol; secondary carboxylic acid amide; carboxamide group; tertiary amine; carboxylic acid ester; secondary alcohol; carboxylic acid; enol; ether; enolate; carboxylic acid derivative; acetal; polyamine; organonitrogen compound; amine; alcohol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the naphthofurans. These are compounds containing a furan ring fused to a naphthalene moeity.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of disseminated <i>Mycobacterium avium</i> complex (MAC) disease in patients with advanced HIV infection.</td></tr><tr><th>Pharmacodynamics</th><td>Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including <i>Pseudomonas aeruginosa</i>) and specifically <i>Mycobacterium tuberculosis</i>. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifabutin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.</td></tr><tr><th>Mechanism of action</th><td>Rifabutin acts via the inhibition of DNA-dependent RNA polymerase in gram-positive and some gram-negative bacteria, leading to a suppression of RNA synthesis and cell death.</td></tr><tr><th>Absorption</th><td>Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>85%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Of the five metabolites that have been identified, 25-O-desacetyl and 31-hydroxy are the most predominant. The former metabolite has an activity equal to the parent drug and contributes up to 10% to the total antimicrobial activity.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Rifabutin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00384">27-O-demethylrifabutin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/386">Details</a></td></tr><tr><td>Rifabutin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00696">25-O-desacetyl rifabutin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/717">Details</a></td></tr><tr><td>Rifabutin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00722">31-hydroxy rifabutin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/743">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>A mass-balance study in three healthy adult volunteers with 14C-labeled rifabutin showed that 53% of the oral dose was excreted in the urine, primarily as metabolites. About 30% of the dose is excreted in the feces.</td></tr><tr><th>Half life</th><td>45 (&#177; 17) hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.69 +/- 0.32 L/hr/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub> = 4.8 g/kg (mouse, male)</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.5507</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9921</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7072</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.9612</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5415</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6516</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.819</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.745</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8909</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6724
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9195
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9687
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5143 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.946
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5416
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.cqici.com">CQ International Co. Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the effect and toxicity of rifabutin.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Rifabutin, may decrease the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase levels/toxicity of rifabutin.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01117">Atovaquone</a></td><td>Rifabutin decreases the effect of atovaquone</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Rifampin reduces bupropion levels</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Rifabutin decreases the effect of buspirone</td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Rifabutin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The rifamycin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00250">Dapsone</a></td><td>Decreased levels of dapsone</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Rifabutin decreases the effect of delavirdine</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Rifabutin may decrease the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The rifamycin decreases the effect of doxycycline</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>Decreased levels/effect of erlotinib</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used.  </td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase levels/toxicity of rifabutin.</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Amprenavir increases the effect and toxicity of rifabutin</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>The rifamycin decreases the effect of haloperidol</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Rifabutin decreases the effect of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Rifabutin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of the contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The rifamycin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Modification of drug levels for both agents</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Rifampin decreases the effect of propafenone</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Rifabutin decreases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Rifabutin decreases the effect of saquinavir</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>The rifamycin decreases the effect of sirolimus</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible decrease in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects. </td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00495">Zidovudine</a></td><td>The rifamycin decreases levels of zidovudine</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>High-fat meals slow the rate of absorption.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>